featured
MRD Response and Outcomes With Fixed-Duration Venetoclax–Rituximab in Relapsed/Refractory CLL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
Blood 2022 May 23;[EPub Ahead of Print], JF Seymour, TJ Kipps, B Eichhorst, J D'Rozario, C Owen, S Assouline, N Lamanna, T Robak, J de la Serna, U Jaeger, G Cartron, M Montillo, C Mellink, B Chyla, A Panchal, T Lu, QJ Wu, Y Jiang, M Lefebure, M Boyer, AP KaterFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.